DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Conditions: Multiple Myeloma in Relapse
Multiple Myeloma

First Posted Date: 2016-01-28

Last Posted Date: 2017-08-28

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02666209

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions: Drug: Paclitaxel
Drug: Ricolinostat
Drug: Bevacizumab

First Posted Date: 2016-01-25

Last Posted Date: 2019-11-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT02661815

Locations: 🇺🇸
Massacusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Drug: Regorafenib

First Posted Date: 2016-01-18

Last Posted Date: 2024-11-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 8

Registration Number: NCT02657551

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Phase 1

Withdrawn

Conditions: Multiple Myeloma
Multiple Myeloma in Relapse
Refractory Multiple Myeloma

Interventions: Drug: GO-203-2C
Drug: Bortezomib

First Posted Date: 2016-01-18

Last Posted Date: 2017-07-05

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02658396

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Phase 2

Withdrawn

Conditions: Solid Tumor

Interventions: Drug: BAY 1000394

First Posted Date: 2016-01-15

Last Posted Date: 2016-07-01

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02656849

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: T-DM1
Drug: Trastuzumab
Drug: Fulvestrant

First Posted Date: 2016-01-15

Last Posted Date: 2022-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT02657343

Locations: 🇺🇸
Massacusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer Radiation

Interventions: Device: Prosigna

First Posted Date: 2016-01-12

Last Posted Date: 2025-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 671

Registration Number: NCT02653755

Locations: 🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States
🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸
Memorial Sloane Kettering Cancer Center, New York, New York, United States

and more 3 locations

An Open-Label Phase II Study of Nivolumab in Adult Participants With Progessive/ Recurrent Meningioma

Phase 2

Active, not recruiting

Conditions: Meningiomas

Interventions: Drug: Ipilimumab - 1 mg/kg
Drug: Nivolumab - 240 mg
Drug: Nivolumab - 480 mg
Drug: Nivolumab - 3 mg/kg
Radiation: External Beam RT

First Posted Date: 2016-01-07

Last Posted Date: 2024-12-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT02648997

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Improving Surgical Decision-making in Young Women With Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Other: qualitative data collection
Other: survey
Other: decision aid

First Posted Date: 2015-12-31

Last Posted Date: 2020-06-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 145

Registration Number: NCT02644382

Gut Decontamination In Pediatric Allogeneic Hematopoietic

Phase 2

Completed

Conditions: Hematopoietic Stem Cell Transplantation (HSCT)
Acute GVH Disease

Interventions: Drug: Vancomycin-polymyxin B

First Posted Date: 2015-12-29

Last Posted Date: 2023-09-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT02641236

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy